Thanks to private funding, 100% of every dollar donated to The Lustgarten Foundation goes directly to pancreatic cancer research.

Research Awards Listing

Research follows dollars, and The Lustgarten Foundation believes that increasing funds for pancreatic cancer research will translate into enhanced patient care, and ultimately, a cure.

The Lustgarten Foundation firmly believes that increasing funds for pancreatic cancer research is the surest path to improved patient care and eventually, to a cure. To date, we have committed more than $120 million to providing the best and brightest minds with the resources to pursue the study and eradication of the disease.

View Award Listings by Year

2015 | 2014 |  2013  |  2012  |  2011  |  2010  | 2009  |  2008  | 2007  |  2006  |  2005  |  2004  |  2003  |  2002  |  2001  |  2000-1998

2013 Research Grants

Matthias Stephan, M.D., Ph.D.
Rapid in Situ Generation of Pancreatic Tumor-Specific T Cells Using DNA Nanocarriers
Fred Hutchinson Cancer Research Center

Gregory Verdine, Ph.D.
Targeting Ras Using Cell-Penetrating Mini-Proteins
Harvard University

Nilofer Azad, M.D.
Analysis Targeting RAS Downstream Signaling with Combination Therapy Using a CDKS Inhibitor with an AKT Inhibitor in Metastatic Pancreatic Cancer
Johns Hopkins University

Elizabeth Jaffe, M.D.
Robert Vonderheide, M.D.
The SU2C - The Lustgarten Foundation Pancreatic Cancer Convergence Dream Team
Transforming Pancreatic Cancer from a Death Sentence to a Treatable Disease
Johns Hopkins University
University of Pennsylvania

Rakesh Jain, M.D. 
Robert Langer, Ph.D.
Targeting Desmoplasia to Improve Drug Delivery and Enhance Treatment of Pancreatic Ductal Adenocarcinoma
Massachusetts General Hospital - Harvard University
Massachusetts Institute of Technology

Ralph Weissleder, M.D., Ph.D.
Exosomes as a Diagnostic and Prognostic Biomarker in Pancreatic Ductual Adenocarcinoma
Memorial Sloan Kettering Cancer Center

David Kelsen, M.D.
A Registry of BRCA Mutation Carrier Patients with Pancreatic Ductal Adenocarcinoma
Memorial Sloan Kettering Cancer Center

Kenneth Yu, Ph.D.
David Tuveson, M.D., Ph.D.
A Two Stage Pilot Study of Single Dose PEGPH20 and Cetuximab in Patients with Pancreatic Ductal Adenocarcinoma Prior to Surgical Resection
Memorial Sloan Kettering Cancer Center
Cold Spring Harbor Laboratory

Ron Evans, Ph.D.
Terry Van Dyke,Ph.D.
In Vivo Analysis of a Vitamin D-Receptor Agonist as a Cancer Therapy Modulator in a Kras/p53 Dependent Murine Model of PDAC
Salk Unstitute for Biological Studies
National Cancer Institute (CAPR)

Raghu Kalluri, M.D., Ph.D.
Exploring the Functional Connection Between Stromal Myofibroblasts and Tumors Immunity in PDAC to Unravel New Therapy Targets.
University of Texas M.D. Anderson Cancer Center

Stephen Fesik, Ph.D.
Targeting of K-RAS Pathways with Small Molecules
Vanderbilt University

David DeNardo, Ph.D.
Targeting CCR2 to Overcome Immunosuppression and Improve Immunotherapy
Washington University

415 Crossways Park Drive, Suite D, Woodbury, NY 11797
Toll Free: 1-866-789-1000 P: 516-737-1550 F: 516-584-6265


2015 website development and design sponsored by Celgene